Bronchial asthma
Conditions
Interventions
Budesonide160 mcg/Formoterol4.5 mcg once 2 inhalation,twice daily
Fluticasone furoate100 mcg /vilanterol2 mcg once 1 inhalation,once daily
Sponsors
Hiroshima Allergy and Respiratory Clinic
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Patient who completely fills the following criteria 1)Man or woman who is 20 years old or older at the time getting informed consent 2)Patient who is diagnosed with asthma 3)Patient who had been administered inhaled corticosteroids of medium dose at 12 weeks over the past 4)Patient who has Value of FeNO more than 35 ppb Inhaled steroids of medium dose, Budesonide(BUD)400-800 mcg/day, or, beclomethasone(BDP-HFA), fluticasone (FP-DPI,HFA), ciclesonide(CIC-HFA), mometasone(MF-DPI)is defined as a 200-400 mcg/day
Exclusion criteria
Exclusion criteria: The patient with the following exclusion criteria is not enrolled 1)Patient with the drug allergy 2)Infection in the absence of effective antimicrobial agents, patients with deep mycosis 3)Patient with tuberculous disease, or respiratory infection 4)Patient with abnormal chest X-ray image 5)Patient with respiratory disease and other respiratory infections in 8 weeks before inclusion 6)Patient is using the beta-blockers, including eye drops or patients with systemic corticosteroids to less than 30 days 7)Patient with serious complications 8)Smoking history of 10 pack years or more and with less than 6 months or by non smoking 9)Patient with pregnancy, or who hope for a pregnancy 10)Patient was deemed inappropriate research attending physician is incorporated into this study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The comparison of amount of change in FeNO with NIOXmino between baseline and after 4 weeks treatment | — |
Secondary
| Measure | Time frame |
|---|---|
| The comparison of the effect in the following background factors after 4week treatment; ACQ score Airway resistance with IOS FEV1.0 Frequency of SABA use | — |
Countries
Japan
Contacts
Public ContactSoichiro Hozawa
Hiroshima Allergy and Respiratory Clinic Department of Respiratory medicine
Outcome results
None listed